Your cholesterol came back normal. That's good news, and I mean that. But I see a lot of people in their 40s, 50s and 60s walk away from that result thinking the heart question is settled. It may not be.
A standard cholesterol panel answers one question well: how much cholesterol is being carried in your blood. It doesn't answer two others that matter. How many particles are carrying it? And did you inherit a particle that raises your risk on its own? That's where ApoB and Lp(a) come in.
What a standard cholesterol panel measures
The number most people watch is LDL cholesterol, the "bad cholesterol." It measures how much cholesterol is riding inside LDL particles. It doesn't count the particles.
Here's the picture I use with patients. Think of cholesterol as cargo and the particles as trucks. The same load can be carried by a few big trucks or a lot of small ones. Your LDL cholesterol measures the cargo. It doesn't tell you how many trucks are on the road.
That matters because cholesterol gets into the artery wall inside these particles (Sniderman 2019). More particles means more chances for some of them to get in and stay there, which is how plaque can start.
ApoB: a closer count of the particles
Each of these artery-damaging particles carries one protein on its surface called apolipoprotein B, or ApoB. Because there's one per particle, measuring ApoB gives a closer estimate of how many are circulating.
Most of the time, LDL cholesterol and ApoB tell a similar story. Sometimes they don't. In a study of more than 27,000 healthy female health professionals followed for about 17 years, women whose LDL cholesterol was on the lower side but whose ApoB was on the higher side had more heart events than their LDL alone would have suggested (Mora 2014). When the two numbers disagree, risk tends to follow ApoB more closely (Sniderman 2019).
This mismatch shows up more often in people with insulin resistance, high triglycerides, prediabetes or type 2 diabetes, or extra fat around the middle. In that pattern the body tends to make more particles, each carrying less cholesterol. LDL cholesterol can look fine while ApoB runs high.
The 2026 cholesterol guideline from the American College of Cardiology and the American Heart Association says ApoB testing can be useful to sharpen risk assessment and guide treatment once LDL cholesterol goals are met, especially in people with high triglycerides, diabetes, or an LDL cholesterol that is already low (Blumenthal 2026).
None of this makes LDL cholesterol a bad test. It's well studied and still an important target. The mistake is treating one good LDL result as the whole answer.
Lp(a): the one you inherit
Lipoprotein(a), usually written Lp(a) and said "L-P-little-a," is a particle many people haven't heard of. It's one of the artery-damaging particles, and high levels are linked with heart attack, stroke and narrowing of the aortic valve (Kronenberg 2022).
Three things set Lp(a) apart:
- It's mostly genetic. More than 90 percent of your level is set by your genes.
- Lifestyle barely moves it. Exercise, which helps so much else, has little or no effect on it.
- It can be high when everything else looks good. High Lp(a) is a risk factor even when LDL cholesterol is very low.
It isn't rare. The European Atherosclerosis Society estimates that about 1.4 billion people worldwide have elevated Lp(a), and it recommends that adults have it measured at least once (Kronenberg 2022). Because the level is largely set early in life, one test tells you a lot. Many adults haven't had it checked. If a parent or sibling had early heart disease or is known to have high Lp(a), it's worth asking whether family members should be tested too.
I want to be straight about where treatment stands. There's no approved medicine made specifically to lower Lp(a) yet. In September 2026, the company behind the first large outcome trial of one such drug, in people who already had heart disease, announced that it lowered Lp(a) but didn't reduce heart events overall. Detailed results are expected in November, and trials of other Lp(a)-lowering drugs are still under way.
There is one encouraging finding for women after menopause. In randomized trials, estrogen taken by mouth lowered Lp(a) by about 20 percent on average, more than estrogen through the skin did (Anagnostis 2017). Separately, in trials where women started hormone therapy within about 10 years of menopause or before age 60, there were fewer deaths and less heart disease than without it, and a Danish trial of oral estradiol in women around age 50 found fewer heart attacks, heart failure hospital stays and deaths over 10 years (Boardman 2015; Schierbeck 2012). These studies don't show that lowering Lp(a) caused that benefit, and women who started later didn't see the same benefit, so hormone therapy isn't a treatment for Lp(a) on its own, but it's one more thing worth knowing for women already weighing it with their clinician.
For now, a high Lp(a) is mainly a reason to take the risks you can change more seriously, and earlier.
Why hormone changes after 40 can shift your numbers
This is where it connects to my work.
For women, menopause itself changes the lipid picture. In SWAN, a long-running U.S. study that followed women of several ethnic backgrounds through midlife, LDL cholesterol and ApoB rose noticeably in the year before and after the final period, more than age alone would explain. That pattern came from about 1,000 women whose natural final period was captured during the study (Matthews 2009). Some research also suggests Lp(a) can rise somewhat in women around menopause (Derby 2009). A cholesterol result from your early 40s may not describe you at 52.
For men, low testosterone often travels with belly fat and insulin resistance, the same pattern that can push ApoB up while LDL looks normal. In a small placebo-controlled crossover trial of 24 men with low testosterone and type 2 diabetes, three months of testosterone improved insulin sensitivity and modestly lowered waist size and total cholesterol compared with placebo (Kapoor 2006). That was a specific group of men with a confirmed deficiency, so it isn't a reason to use testosterone for cholesterol.
For both, thyroid matters. An underactive thyroid can slow how the liver clears these particles. In a small study of 13 people with a mildly underactive thyroid, ApoB fell by close to 20 percent after two months of thyroid hormone treatment (Arem 1990). That study had no comparison group, so it shows a change, not proof of cause.
Hormones aren't a cholesterol treatment, and I don't use them that way. But when hormones shift, your lipids can shift with them. That's a good reason for a midlife check with the full picture in view.
What's worth asking about
If your panel came back normal and you're over 40, here's what I'd want to talk through at your next visit:
- ApoB. A closer count of the particles that can get into the artery wall.
- Lp(a), at least once. If it hasn't been checked, ask about it.
- Triglycerides and HDL, read together. High triglycerides with low HDL can be a clue to insulin resistance.
- Fasting insulin and A1C. Blood sugar can stay normal for years while insulin works harder behind the scenes. I wrote about that in Your Glucose Is Normal. Your Insulin Might Not Be.
- Thyroid, and for women, where you are in the menopause transition. Both can move these numbers.
- The rest of the picture. Blood pressure, smoking, family history of early heart disease, and kidney function all count. When the next step still isn't clear, a coronary calcium scan can sometimes help.
One number isn't a diagnosis, and one high result isn't a reason to panic. These results mean the most when your clinician reads them together, with your history, and over time.
What you can do with the answer
If ApoB comes back high, the levers are familiar: nutrition, activity, muscle, sleep, body composition, and treating a real hormone or thyroid problem if one is there. Some people will also need medication. That isn't a failure. It usually means the remaining risk is high enough to justify another tool. If you're curious which supplements have real trial data behind them, and which don't, I covered that in Which Supplements Actually Improve Your Lipid Panel?
If Lp(a) comes back high, exercise and diet won't do much to lower it. What it changes is how seriously you and your clinician treat everything else.
The bottom line
A normal cholesterol result is useful information. It isn't proof that your heart risk is low. ApoB tells you more about how many particles are out there. Lp(a) tells you about a risk you may have been born with. Both are simple blood tests, and both are worth a conversation. For a deeper look at the science, see My LDL Cholesterol Is Normal. Could I Still Be at Risk?
Where to take this next
Already a 4Ever Young patient? Talk with your local clinic team. Bring your most recent labs and ask whether ApoB and Lp(a) make sense for you.
Not near a 4Ever Young clinic? Email drwilcox@precisionhormoneconsulting.com to request your free virtual consultation. Virtual consultations are available in Texas, Arizona, Florida, Oregon and Colorado.
Darrell Wilcox, MD | @wellnessdoc_4everyoung on Instagram
Wellness Doc · 4Ever Young
Sources
Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, Ference BA. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287-1295. PMID: 31642874.
Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014;129(5):553-561. PMID: 24345402.
Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. PMID: 41824552.
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. PMID: 36036785.
Anagnostis P, Galanis P, Chatzistergiou V, Stevenson JC, Godsland IF, Lambrinoudaki I, Theodorou M, Goulis DG. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: a systematic review and meta-analysis. Maturitas. 2017;99:27-36. PMID: 28364865.
Boardman HM, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, Gabriel Sanchez R, Knight B. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;(3):CD002229. PMID: 25754617.
Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, Køber L, Jensen JE. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. PMID: 23048011.
Derby CA, Crawford SL, Pasternak RC, Sowers M, Sternfeld B, Matthews KA. Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. Am J Epidemiol. 2009;169(11):1352-1361. PMID: 19357323.
Matthews KA, Crawford SL, Chae CU, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol. 2009;54(25):2366-2373. PMID: 20082925.
Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899-906. PMID: 16728551.
Arem R, Patsch W. Lipoprotein and apolipoprotein levels in subclinical hypothyroidism. Effect of levothyroxine therapy. Arch Intern Med. 1990;150(10):2097-2100. PMID: 2222095.
Novartis. Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD). Press release, September 4, 2026. ClinicalTrials.gov NCT04023552.
This content is for educational purposes only and does not constitute medical advice. Heart risk can't be judged from LDL cholesterol, ApoB, Lp(a), or any other single lab value alone, and hormone therapy is appropriate only when a real deficiency or clinical reason has been confirmed, not because of a lipid result alone. Testing and treatment decisions deserve individualized evaluation with a licensed clinician who knows your history. Do not start, stop, or change any medication without guidance from your treating clinician. Individual results vary, and no outcome is guaranteed. Dr. Wilcox is licensed to practice in Texas, Arizona, Colorado, Oregon, and Florida.
